Download PDF
Pharmacopsychiatry 2003; 36: 207-214
DOI: 10.1055/s-2003-45132
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Stress Responsive Neurohormones in Depression and Anxiety

A. Ströhle1 , F. Holsboer2
  • 1Department of Psychiatry and Psychotherapy, Charité - University Medicine Berlin, Campus Charité-Mitte (CCM), Berlin, Germany
  • 2Max Planck Institute of Psychiatry, Munich, Germany
Further Information

Publication History

Publication Date:
15 December 2003 (online)

Also available at
    Permissions and Reprints

Clinical and preclinical studies have gathered substantial evidence that stress response alterations play a major role in the development of major depression, panic disorder and posttraumatic stress disorder. The stress response, the hypothalamic pituitary adrenocortical (HPA) system and its modulation by CRH, corticosteroids and their receptors as well as the role of natriuretic peptides and neuroactive steroids are described. Examplarily, we review the role of the HPA system in major depression, panic disorder and posttraumatic stress disorder as well as its possible relevance for treatment. Impaired glucocorticoid receptor function in major depression is associated with an excessive release of neurohormones, like CRH to which a number of signs and symptoms characteristic of depression can be ascribed. In panic disorder, a role of central CRH in panic attacks has been suggested. Atrial natriuretic peptide (ANP) is causally involved in sodium lactate-induced panic attacks. Furthermore, preclinical and clinical data on its anxiolytic activity suggest that non-peptidergic ANP receptor ligands may be of potential use in the treatment of anxiety disorders. Recent data further suggest a role of 3α-reduced neuroactive steroids in major depression, panic attacks and panic disorder. Posttraumatic stress disorder is characterized by a peripheral hyporesponsive HPA-system and elevated CRH concentrations in CSF. This dissociation is probably related to an increased risk for this disorder. Antidepressants are effective both in depression and anxiety disorders and have major effects on the HPA-system, especially on glucocorticoid and mineralocorticoid receptors. Normalization of HPA-system abnormalities is a strong predictor of the clinical course, at least in major depression and panic disorder. CRH-R1 or glucorticoid receptor antagonists and ANP receptor agonists are currently being studied and may provide future treatment options more closely related to the pathophysiology of the disorders.

References

  • 1 Abelson J L, Curtis C G. Hypothalamic-pituitary-adrenal axis activity in panic disorder: 24-hour secretion of corticotropin and cortisol.  Arch Gen Psychiatry. 1996;  53 323-331
    PubMedGoogle Scholar
  • 2 Bandelow B, Wedekind D, Pauls J, Broocks A, Hajak G, Rüther E. Salivary cortisol in panic attacks.  Am J Psychiatry. 2000;  157 454-456
    CrossrefPubMedGoogle Scholar
  • 3 Belanoff J K, Gross K, Yager A, Schatzberg A F. Corticosteroids and cognition.  J Psychiatr Res. 2001;  35 127-145
    CrossrefPubMedGoogle Scholar
  • 4 Bremner J D, Licinio J, Darwell A, Krystal J H, Owens M J, Soutwick S M, Nemeroff C B, Charney D S. Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder.  Am J Psychiatry. 1997;  154 624-629
    PubMedGoogle Scholar
  • 5 Carroll B J, Feinberg M, Greden J F. A specific laboratory test for the diagnosis of melancholia.  Arch Gen Psychiatry. 1981;  38 15-22
    PubMedGoogle Scholar
  • 6 Chalmers D T, Lowenberg T W, de Souza E B. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: Comparison with CRF1 receptor mRNA expression.  J Neurosci. 1995;  15 6340-6350
    PubMedGoogle Scholar
  • 7 Curtis G C, Cameron O G, Neese R M. The dexamethasone suppression test in panic disorder and agoraphobia.  Am J Psychiatry. 1982;  139 1043-1046
    PubMedGoogle Scholar
  • 8 de Bold A J. Atrial natriuretic factor a hormone produced by the heart.  Science. 1985;  230 767-770
    CrossrefPubMedGoogle Scholar
  • 9 de Kloet E R. Brain corticosteroid receptor balance and homeostatic control.  Front Neuroendocrinol. 1991;  12 95-164
    PubMedGoogle Scholar
  • 10 Deuschle M, Schweiger U, Weber B, Gotthart U, Korner A, Schmider J, Lammers C H, Heuser I. Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls.  J Clin Endocr & Metab. 1997;  82 234-238
    CrossrefPubMedGoogle Scholar
  • 11 Duman R S, Heninger G R, Nestler E J. A molecular and cellular theory of depression.  Arch Gen Psychiatry. 1997;  54 597-606
    CrossrefPubMedGoogle Scholar
  • 12 Dunn A J, Berridge C W. Physiological and behavioral responses to corticotropin releasing factor administration: Is CRF a mediator of anxiety or stress response.  Brain Res Rev. 1990;  15 1-100
    CrossrefPubMedGoogle Scholar
  • 13 Geriacoti T D, Orth D N, Ekhator N N, Blumenkopf B, Loosen P T. Serial cerebrospinal fluid corticotropin-releasing hormone concentrations in healthy and depressed humans.  J Clin Endocrinol Metab. 1992;  74 1325-1330
    CrossrefPubMedGoogle Scholar
  • 14 Griffin L D, Mellon S H. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes.  Proc Natl Acad Sci. 1999;  96 13 512-13 517
    PubMedGoogle Scholar
  • 15 Heuser I JE, Schweiger U, Gotthardt U, Schmider J, Lammers C H, Dettling M, Yassouridis A, Holsboer F. Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and in normal comparison subjects.  Am J Psychiatry. 1996;  153 93-99
    PubMedGoogle Scholar
  • 16 Heuser I, Bisette G, Dettling M, Schweiger U, Gotthardt U, Schmider J, Lammers C H, Nemeroff C B, Holsboer F. Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment.  Depress Anxiety. 1998;  8 71-79
    PubMedGoogle Scholar
  • 17 Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety.  J Psychiatr Res. 1999;  33 181-214
    CrossrefPubMedGoogle Scholar
  • 18 Holsboer F. The corticosteroid receptor hypothesis of depression.  Neuropsychopharmacology. 2000;  23 477-501
    CrossrefPubMedGoogle Scholar
  • 19 Holsboer F, von Bardeleben U, Gerken A, Stalla G K, Müller O A. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression.  N Engl J Med. 1984;  1984 1127
    PubMedGoogle Scholar
  • 20 Holsboer F, von Bardeleben U, Wiedemann K, Müller O A, Stalla G K. Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression-Implications for pathophysiology of DST nonsuppression.  Biol Psychiatry. 1987;  22 228-234
    CrossrefPubMedGoogle Scholar
  • 21 Holsboer F, von Bardeleben U, Buller R, Heuser I, Steiger A. Stimulation response to corticotropin-releasing hormone (CRH) in patients with depression alcoholism and panic disorder.  Horm Metab Res. 1987;  19 80-88
    PubMedGoogle Scholar
  • 22 Holsboer F, Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation.  Endocr Rev. 1996;  17 187-205
    CrossrefPubMedGoogle Scholar
  • 23 Jolkonen J, Lepola U, Bissette G, Nemeroff C, Riekkinen P. CSF corticotropin-releasing factor is not affected in panic disorder.  Biol Psychiatry. 1987;  33 136-138
    PubMedGoogle Scholar
  • 24 Kathol R G, Noyes R, Lopez A L, Reich J H. Relationship of urinary free cortisol levels in patients with panic disorder to symptoms of depression and agoraphobia.  Psychiatry Res. 1988;  24 211-221
    CrossrefPubMedGoogle Scholar
  • 25 Kellner M, Wiedemann K, Holsboer F. ANF inhibits the CRH-stimulated secretion of ACTH and cortisol in man.  Life Sci. 1982;  50 1835-1842
    PubMedGoogle Scholar
  • 26 Kellner M, Herzog L, Holsboer F, Wiedemann K. A possible role of atrial natriuretic hormone in pituitary-adrenocortical unresponsiveness in lactate-induced panic.  Am J Psychiatry. 1995;  152 1365-1367
    PubMedGoogle Scholar
  • 27 Malizia A, Cunningham V J, Bell C J, Liddle P F, Jones T, Nutt D J. Decreased brain GABAA benzodiazepine receptor binding in panic disorder.  Arch Gen Psychiatry. 1998;  47 917-925
    PubMedGoogle Scholar
  • 28 Modell S, Lauer C J, Schreiber W, Huber J, Krieg J -C, Holsboer F. Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders.  Neuropsychopharmacology. 1998;  18 253-262
    CrossrefPubMedGoogle Scholar
  • 29 Murphy B EP, Filipini D, Ghardirian A M. Possible use of glucocorticoid receptor antagonists in the treatment of major depression: Preliminary results using RU486.  J Psychiatry Neurosci. 1993;  18 209-213
    PubMedGoogle Scholar
  • 30 Nemeroff C B, Bisette G, Akil H, Fink M. Neuropeptide concentrations in the CSF of depressed patients treated with electroconvulsive therapy.  Br J Psychiatry. 1993;  158 9-63
    PubMedGoogle Scholar
  • 31 Nutt D J, Glue P, Lawson C, Wilson S. Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder.  Arch Gen Psychiatry. 1990;  47 917-925
    PubMedGoogle Scholar
  • 32 O’Dwyer A M, Lightman S L, Marks M, Checkley S A. Treatment of major depression with metyrapone and hydrocortisone.  J Affect Disord. 1995;  33 123-128
    CrossrefPubMedGoogle Scholar
  • 33 Patchev V K, Montkowski A, Rouskova D, Koranyi L, Holsboer F, Almeida O. Neonatal treatment of rats with the neuroactive steroid tetrahydrodeoxycorticosterone (THDOC) abolishes the behavioral and neuroendocrine consequences of adverse early life events.  J Clin Invest. 1997;  99 962-966
    PubMedGoogle Scholar
  • 34 Patchev V K, Hassan A H, Holsboer F, Almeida O FX. The neurosteroid tetrahydroprogesterone attenuates the endocrine response to stress and exerts glucocorticoid-like effects on vasopressin gene transcription in the rat hypothalamus.  Neuropsychopharmacology. 1996;  15 533-540
    CrossrefPubMedGoogle Scholar
  • 35 Paul S M, Purdy R H. Neuroactive steroids.  FASEB J. 1992;  6 2311-2322
    PubMedGoogle Scholar
  • 36 Reul J MHM, Stec I, Söder M, Holsboer F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system.  Endocrinology. 1993;  133 312-320
    CrossrefPubMedGoogle Scholar
  • 37 Romeo E, Ströhle A, di Michele F, Spaletta G, Hermann B, Holsboer F, Pasini A, Rupprecht R. Effects of antidepressant treatment on neuroactive steroids in major depression.  Am J Psychiatry. 1998;  155 910-913
    PubMedGoogle Scholar
  • 38 Roy-Byrne P P, Uhde T W, Post R M, Gallucci W, Chousos G P, Gold P W. The corticotropin-releasing hormone stimulation test in patients with panic disorder.  Am J Psychiatry. 1986;  143 896-899
    PubMedGoogle Scholar
  • 39 Rubin R T, Phillips J J, Sado T F, McCracken J T. Adrenal gland volume in major depression. Increase during the depressive episode and decrease with successful treatment.  Arch Gen Psychiatry. 1995;  52 213-218
    PubMedGoogle Scholar
  • 40 Rupprecht R, Ströhle A, Hermann B, di Michele F, Spaletta G, Pasini A, Holsboer F, Romeo E. Neuroactive steroid concentrations following metyrapone administration in depressed patients and healthy volunteers.  Biol Psychiatry. 1998;  44 912-914
    CrossrefPubMedGoogle Scholar
  • 41 Rupprecht R, Holsboer F. Neuroactive steroids: Mechanisms of action and neuropsychopharmacological perspectives.  Trends Neurosci. 1999;  22 410-416
    CrossrefPubMedGoogle Scholar
  • 42 Schatzberg A F, Rothschild A J, Langlais P J, Bird E D, Cole J O. A corticosteroid/dopamine hypothesis for psychotic depression and related states.  J Psychiatric Res. 1984;  19 57-64
    PubMedGoogle Scholar
  • 43 Schreiber W, Lauer C J, Krumrey K, Holsboer F, Krieg J C. Dysregulation of the hypothalamic-pituitary-adrenocortical system in panic disorder.  Neuropsychopharmacology. 1996;  15 7-15
    CrossrefPubMedGoogle Scholar
  • 44 Stenzel-Poore M P, Heinrichs S C, Rivest S, Koob G F, Vale W W. Overproduction of corticotropin-releasing factor in transgenic mice: A genetic model of anxiogenic behavior.  J Neurosci. 1994;  14 2579-2584
    PubMedGoogle Scholar
  • 45 Ströhle A, Jahn H, Montkowski A, Liebsch G, Boll E, Landgraf R, Holsboer F, Wiedemann K. Central and peripheral administration of atriopeptin is anxiolytic in rats.  Neuroendocrinology. 1997;  65 210-215
    PubMedGoogle Scholar
  • 46 Ströhle A, Kellner M, Holsboer F, Wiedemann K. Atrial natriuretic hormone decreases endocrine response to a combined dexamethasone corticotropin-releasing hormone test.  Biol Psychiatry. 1998;  43 371-375
    CrossrefPubMedGoogle Scholar
  • 47 Ströhle A, Kellner M, Yassouridis A, Holsboer F, Wiedemann K. Effect of flumazenil in lactate-sensitive patients with panic disorder.  Am J Psychiatry. 1998;  155 610-612
    PubMedGoogle Scholar
  • 48 Ströhle A, Kellner M, Holsboer F, Wiedemann K. Behavioral, neuroendocrine and cardiovascular response to flumazenil: No evidence for an altered benzodiazepine receptor sensitivity in panic disorder.  Biol Psychiatry. 1999;  45 321-326
    CrossrefPubMedGoogle Scholar
  • 49 Ströhle A, Romeo E, Hermann B, di Micelle F, Spaletta G, Pasini A, Holsboer F, Rupprecht R. Concentrations of 3α-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery.  Biol Psychiatry. 1999;  45 274-277
    CrossrefPubMedGoogle Scholar
  • 50 Ströhle A, Kellner M, Holsboer F, Wiedemann K. Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder.  Am J Psychiatry. 2001;  158 1514-1516
    Google Scholar
  • 51 Ströhle A, Romeo E, di Michele F, Pasini A, Yassouridis A, Holsboer F, Rupprecht R. GABAA receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment.  Am J Psychiatry. 2002;  159 145-147
    CrossrefPubMedGoogle Scholar
  • 52 Ströhle A, Romeo E, di Michele F, Pasini A, Hermann B, Gajewsky G, Holsboer F, Rupprecht R. Induced panic attacks shift GABAA receptor modulatory neuroactive steroid composition in patients with panic disorder.  Arch Gen Psychiatry. 2003;  60 161-168
    PubMedGoogle Scholar
  • 53 Timpl P, Spanagel R, Sillaber I, Kresse A, Reul J MHM, Stalla G K, Blanquet V, Steckler T, Holsboer F, Wurst W. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing homone receptor 1.  Nature Genet. 1998;  19 162-166
    CrossrefPubMedGoogle Scholar
  • 54 Uzunov D P, Cooper T B, Costa E, Guidotti A. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography.  Proc Natl Acad Sci USA. 1996;  93 12599-12604
    CrossrefPubMedGoogle Scholar
  • 55 Uzunova V, Sheline Y, Davis J M, Rasmusson A, Uzunov D P, Costa E, Guidotti A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine.  Proc Natl Acad Sci USA. 1998;  95 3239-3244
    CrossrefPubMedGoogle Scholar
  • 56 Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphine.  Science. 1981;  213 1394-1397
    CrossrefPubMedGoogle Scholar
  • 57 Wiedemann K, Jahn H, Yassouridis A, Kellner M. Anxiolytic activity of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks.  Arch Gen Psychiatry. 2001;  58 371-377
    CrossrefPubMedGoogle Scholar
  • 58 Wolkowitz O M, Reus V I, Chan T, Manfredi F, Raum W, Johnson R, Canick J. Antiglucocorticoid treatment of depression: Double blind ketokonazole.  Biol Psychiatry. 1998;  45 1070-1074
    PubMedGoogle Scholar
  • 59 Woods S W, Charney D S, McPherson C A, Gradman A H, Heninger G R. Situational panic attacks - Behavioral, physiologic, and biochemical characterization.  Arch Gen Psychiatry. 1987;  44 365-375
    PubMedGoogle Scholar
  • 60 Yehuda R, Boisneau D, Mason J W, Giller E L. Relationship between lymphocyte glucocorticoid receptor number and urinary free cortisol excretion in mood, anxiety, and psychotic disorder.  Biol Psychiatry. 1993;  34 18-25
    CrossrefPubMedGoogle Scholar
  • 61 Yehuda R, Soutwick S M, Krystal J H, Bremner D, Charney D S, Mason J W. Enhanced suppression of cortisol following dexamethasone administration in posttraumatic stress disorder.  Am J Psychiatry. 1993;  150 83-86
    PubMedGoogle Scholar
  • 62 Zobel A, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: A prospective study.  J Psychiatr Res. 2001;  35 83-94
    CrossrefPubMedGoogle Scholar
  • 63 Zobel A W, Nickel T, Künzel H E, Ackl N, Sonntag A, Ising M, Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: The first 20 patients treated.  J Psychiatr Res. 2000;  34 171-181
    CrossrefPubMedGoogle Scholar

Andreas Ströhle, MD

Department of Psychiatry and Psychotherapy

Charité - University Medicine Berlin

Campus Charité-Mitte (CCM)

Schumannstr. 20/21

10117 Berlin

Germany

Phone: +49 (30) 450 517034

Fax: +49 (30) 450 517094

Email: andreas.stroehle@charite.de

      >